Mechanistic description
Convergence hypothesis: NRF2 (NFE2L2) is the central transcriptional regulator whose failure explains parallel proteostatic collapse in both PD and AD, making it a high-priority cross-disease target.
PD-specific mechanism: NRF2 regulates ARE-containing genes (HMOX1, NQO1, GCLC, GSTM1) that detoxify reactive oxygen species generated by mitochondrial dysfunction and neuromelanin iron accumulation. In PD, KEAP1 releases NRF2 in early disease to compensate, but chronic oxidative stress (elevated 4-HNE, 8-OHdG in substantia nigra) eventually overwhelms this response, leading to NRF2 nuclear translocation failure. The resulting proteasome (PSMB5, PSMD4) and autophagy (LAMP2A, GABARAP) failure accelerates α-synuclein aggregation.
AD-specific mechanism: NRF2 activity declines with age in AD brain. Amyloid-beta 42 (via RAGE/NF-κB) and phosphorylated tau (via GSK3B) both suppress NRF2 transcription and promote KEAP1 sequestration. This reduces expression of HMOX1, NQO1, and proteasome subunits PSMB1/PSMB5, impairing clearance of both Abeta and tau aggregates.
Shared molecular targets (2+ per disease): • NFE2L2/NRF2 transcription factor (PD: compensates for mitochondrial ROS; AD: declines with age) • KEAP1 (PD: NRF2 repressor; AD: NRF2 repressor via p62/SQSTM1 pathway) — both sequester NRF2 • HMOX1 (PD: heme oxygenase-1 antioxidant response; AD: same) — shared oxidative stress marker • SQSTM1/p62 (PD: mitophagy adaptor; AD: bridges tau ubiquitination to autophagic clearance) • PSMB5/PSMD4 (PD: proteasome subunit reduced by α-synuclein oligomers; AD: same)
Falsifiable predictions:
- NRF2 activator (dimethyl fumarate or PB002) will reduce both soluble α-synuclein (Ser129-P) and total tau (Tau5) in A53T SNCA transgenic mice after 8 weeks of treatment.
- KEAP1/NRF2/CUL3 ratio in post-mortem PD putamen and AD hippocampus will show KEAP1 elevated >2-fold and NRF2 reduced >50% compared to age-matched controls.
- p62/SQSTM1 phosphorylation (S403) will be reduced in PD and AD brains, correlating with impaired mitophagy and ubiquitin-proteasome system failure.
Cross-references: Bridges h-ec9e48df (NRF2 Activation to Counteract RGS6 Deficiency in PD) and AD NRF2 pathways.
Evidence for (5)
Berberine ameliorates iron levels and ferroptosis in the brain of 3 × Tg-AD mice.
Oxidative stress in Alzheimer's disease: current knowledge of signaling pathways and therapeutics.
Therapeutic effect of nicotinamide mononucleotide on Alzheimer's disease through activating autophagy and anti-oxidative stress.
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?